All these have suggested that paeoniflorin might improve RA by inhibiting inflammation mediated by the ROCK/NF-B signaling pathway
the FDA has stated it lacks sufficient information to know whether the substance would cause harm when administered to humans Evidence snapshot: The evidence base is almost entirely preclinical, decades of animal (largely rat) studies, mostly from one Croatian research group (Sikiric et al., University of Zagreb), with a single small human trial under the brand name "Bepecin" (around 2015) that did not lead to any FDA-approved use
With daily dosing over that timeframe, BDNF-related signaling can start to blunt, and the brains compensatory mechanisms downregulating growth-factor receptor sensitivity start to come into play
Johnson, M.R., et al
Il est noter que cette dose est autorise depuis le 17 fevrier 2026, et que le stylo injecteur de 7,2 mg sera disponible d'ici la fin de l'anne 2026
Plus, for Wegovy, hes not sure that theres enough of a clinical need for it based on the clinical trial results so far
